Current state of the art of Talimogene laherparepvec (T-VEC) - a type of Immunotherapy. An Overview.

Download or read book Current state of the art of Talimogene laherparepvec (T-VEC) - a type of Immunotherapy. An Overview. written by Dr. Hakim. K. Saboowala and published by Dr.Hakim Saboowala. This book was released on 2024-01-06 with total page 40 pages. Available in PDF, EPUB and Kindle. Book excerpt: Current state of the art of Talimogene laherparepvec (T-VEC) - a type of Immunotherapy. An Overview. Talimogene laherparepvec (T-VEC) is the first oncolytic viral immunotherapy to be approved for the local treatment of unresectable metastatic stage IIIB/C–IVM1a melanoma. Its direct intratumoral injection aim to trigger local and systemic immunologic responses leading to tumour cell lysis, followed by release of tumour-derived antigens and subsequent activation of tumour-specific effector T-cells. Its approval has fuelled the interest to study its possible synergy with other immunotherapeutic in preclinical models as well as in clinical contexts. In fact, it has been shown that intra- tumoral administration of this immunostimulatory agent successfully synergizes with *immune checkpoint inhibitors-They block proteins that stop the immune system from attacking the cancer cells Thus, it is strived to review the current state of the art of T-VEC treatment when used in monotherapy or in combination with immune checkpoint inhibitors, describing the strong rationale of its development, the adverse events of interest and the clinical outcome in selected patient’s populations. …Dr. H. K. Saboowala. M.B.(Bom) .M.R.S.H.(London)